Breast Cancer

Preclinical progress reported at the Society of Nuclear Medicine meeting

Published in Women's Health Weekly, August 1st, 2002

Immunomedics, Inc., (IMMU) announced that a presentation at the 49th annual meeting of the Society of Nuclear Medicine reported on the progress of a new antibody-based therapeutic in animals with transplanted human breast cancer.

This preclinical study evaluated an antibody known as humanized RS7 (hRS7) that targets breast, lung, prostate, and ovarian cancers, identifying a tumor-associated molecule named "epithelial glycoprotein-1."

In this study, the hRS7 antibody was labeled with iodine-131 (I-131) using the company's recently patented method that improves the length of time the I-131 stays attached to the antibody. This new labeling method...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2002-08-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry